Additional Ownership Interest in MD Anderson Cancer Center Proton Therapy Center -- On August 12, 2015, the Company closed the acquisition of additional ownership interest of The University of Texas MDACC
Proton Therapy Center from an existing owner of the general partner.
He was a much sought-after speaker and was known at MDACC
as the ambassador of the pathology department.
Alvos was co-founded in 2010 by the MDACC
developers of the technology, Drs.
Anderson Cancer Center (MDACC
) and licensed from MDACC
Participants of the board meeting included members of the board of directors of MDACC
PTC, members of the Advisory Board of MDACC
PTC as well as management teams from both the Company and MDACC
We have established regular business and academic exchange and communication programs with MDACC
Its aim is to address the challenge of increasing the efficacy of cancer healthcare globally through personalized therapy, in diverse populations from North and South America, Europe, Asia, Africa and the Middle East," said John Mendelsohn, President of MDACC
and Chair of the WIN Consortium.
Professor of Urology and Cancer Biology and Director of the MDACC
Prostate Outreach Program at The University of Texas MD Anderson Cancer Center, said, "GE's imaging technology could help more clearly distinguish nerves during surgery facilitating surgical management.
RiboMed subsequently developed a robust G-CIMP biomarker test that shows concordance with the MDACC
clinical DNA Methylation data correlating CIMP Methylation status with patient survival times.
This was achieved by correlating the predicted primary origin assigned by miRview mets with the comprehensive diagnostic work-up conducted at MDACC
, which included surgical pathology, laboratory tests, imaging and a treatment-response follow-up.
In a preliminary study published in May 2008 in Breast Cancer Research (1) conducted on 133 patients, MDACC
researchers had found that, among 852 genomic indexes describing biological pathways, the GGi was one of the most promising candidate for predicting response to chemotherapy.
The Company recently entered into an option agreement with MDACC
for some of the cancer stem cell technologies that were developed at Dr.